|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Interventions listed in this trial | ||||
| cisplatin | |||||
| irinotecan hydrochloride | |||||
| paclitaxel | |||||
| 2 | Additional drug interventions recognized in this trial | ||||
| Camptothecin | |||||
| Irinotecan | |||||
| 3 | More general drug interventions related to this trial | ||||
| Antimitotic Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Enzyme Inhibitors | |||||
| Mitosis Modulators | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| Tubulin Modulators | |||||
| 4 | Sponsors listed in this trial | ||||
| Memorial Sloan-Kettering Cancer Center | |||||
| National Cancer Institute (NCI) | |||||